NICE recommends MSD’s pembrolizumab to treat melanoma
Source: Pharmaceutical Business Review, September 2022
The UK National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab (Keytruda) manufactured by MSD to treat melanoma, the most common form of skin cancer.
The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma.
This drug is said to be the first NICE-recommended treatment for this stage of melanoma (2B and 2C) following surgery for the removal of tumours.